Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities
The presence of baseline IC-Abs may not be associated with the occurrence of post-ICI neurotoxicities in patients with SCLC. However, anti-Hu antibody positivity correlates with an increased risk of irAEs of any type. Larger studies are needed to assess the safety of ICI therapy in patients with SCLC harbouring neural antibodies and to investigate their potential role as predictive biomarkers of post-ICI neurotoxicities.
Authors
- Simone Rossi (ORCID: https://orcid.org/0000-0001-7044-983X)
- Tania Silvestri
- Davide Campana (ORCID: https://orcid.org/0000-0002-4615-7340)
- B. Lenzi
- Rita Rinaldi (ORCID: https://orcid.org/0000-0002-4564-7284)
- Maria Guarino (ORCID: https://orcid.org/0000-0002-0460-4122)
- Elisa Andrini (ORCID: https://orcid.org/0000-0003-2952-1507)
- Giuseppe Lamberti (ORCID: https://orcid.org/0000-0003-3069-7630)
- Maria Giovanna Formelli
- Adriana Di Odoardo (ORCID: https://orcid.org/0009-0003-0529-5274)
Institutions
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Azienda USL di Bologna (IT)
- Istituto delle Scienze Neurologiche di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1681765
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Ministero della Salute